Table 1.

Recent population pharmacokinetic (PK) and pharmacokinetic–pharmacodynamic studies of enoxaparin

Author	N	Year	Compartments in PK model	Final body size descriptor on Vc	Final covariates on CL	Body size descriptor used in CLCR calculation	BSV (% CV) on CL (final model)	BSV (% CV) Vc (final model)	RUV (IU ml−1‡ or % CV§)
Bruno [31]	448	2002	1	Nil	Wt, CLCR	Wt	26.9	56.1*	21.5%
Hulot [30]	60	2004	1	Wt*	Wt, SCr gender	N/A	23	54*	0.15
Hulot [40]	532	2005	1	Wt*	Wt, SCr gender	N/A	27	50*	0.14
Sanchez-Pena [42]	546	2005	1	Wt*	Wt	N/A	33	30*	0.09
Kane-Gill [43]	67	2005	1	Nil	Wt	N/A	70	57*	N/P
Green [15]	96	2002	2	Wt	LBW	N/A	35.6	58	0.08
Green [14]	38	2004	2	Wt	CLCR†	IBW	32.7	34.4	0.05, 20%¶
Berges [44]	189	2007	2	Wt	Wt, CLCR	MDRD	26	15	30%
Feng [29]	48	2006	2	Wt	CLCR†	IBW	40.7	29.4	0.13, 12%¶**44%††
Barras	118	2009	2	LBW	CLCR†	LBW	37.8	35.6	0.09

V_c, central volume of distribution; CL, clearance; N, number of subjects in the study; BSV, between-subject variability; RUV, residual unexplained variability; CL_CR, creatinine clearance calculated using the Cockcroft–Gault equation [18]; Wt, total body weight; N/A, not applicable; SCr, serum creatinine concentration; LBW, lean body weight; IBW, ideal body weight; MDRD, modification of diet in renal disease formula; N/P, not presented; Year, year of publication.

^*One-compartment model, therefore results represent total volume of distribution.

^†Denotes combined renal and nonrenal clearance model.

^‡Additive residual error model.

^§Proportional residual error model.

^¶Combined additive and proportional residual error model.

^**General medical subjects.

^††Intensive care subjects.